BMS Exercises its Option to Globally License Obsidian’s CD40L Cell Therapy

 BMS Exercises its Option to Globally License Obsidian’s CD40L Cell Therapy

BMS Exercises its Option to Globally License Obsidian’s CD40L Cell Therapy

Shots:

  • BMS has exercised its option to an exclusive WW license to a cell therapy based on Obsidian’s cytoDRiVE technology for the controlled expression of the immunomodulatory factor CD40L
  • In 2019, the companies collaborated to develop novel cell therapies, under which Obsidian is eligible to receive milestones and royalties on sales of therapies. Exercising the option marks BMS’ first opt in decision
  • Obsidian’s cytoDRiVE technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: BMS

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post